C4 Therapeutics said it will present new Phase 1 biomarker data on cemsidomide at IMS26, highlighting its immunomodulatory effects in multiple myeloma. The candidate is being studied with dexamethasone and targets IKZF1 and IKZF3.
published
C4 Therapeutics said it will present new Phase 1 biomarker data on cemsidomide at IMS26, highlighting its immunomodulatory effects in multiple myeloma. The candidate is being studied with dexamethasone and targets IKZF1 and IKZF3.
Latest documented BWB result
$APP market result
I Sold the $APP $310 Puts for Friday for $3 - been selling Puts on $APP every week with that hard floor of $300 and the high premium
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.